HEPA Archives | BioTuesdays

Developments

Hepion Pharma posts preclinical data supporting two-pronged approach treating COVID-19 with CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that its anti-fibrotic drug candidate, CRV431, was efficacious in two distinct preclinical research models related to COVID-19 disease. CRV431 demonstrated strong anti...

July 7, 2020

Developments

Hepion advances to final dosing level in ongoing Phase 1 study of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) advanced to the final dose level of CRV431 in its ongoing Phase 1 multiple ascending dose trial. The clinical trial management team determined the 300 mg dosing level to be safe and...

June 29, 2020

Developments

Hepion Pharma CRV431 shows efficacy in kidney fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) CRV431 demonstrated antifibrotic activity in an experimental model of renal fibrosis. The study, which was conducted by SMC Laboratories in Tokyo, Japan, evaluated CRV431 in the...

June 22, 2020

Executive Moves

Hepion names drug development expert, Dr. Peter Wijngaard, to its board

Hepion Pharmaceuticals (NASDAQ:HEPA) appointed industry veteran, Dr. Peter Wijngaard, to its board of directors. “Dr. Wijngaard provided invaluable guidance to Hepion’s management team during our earlier work on...

June 10, 2020

Developments

Hepion advances to fourth dosing level in ongoing Phase 1 study of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) advanced to the fourth dose level of CRV431 in its ongoing Phase 1 multiple ascending dose trial. The clinical trial management team determined the 225 mg dosing level to be safe and...

May 20, 2020

Developments

Hepion CRV431 to advance to Phase 2a trial for NASH fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) is planning to commence a Phase 2a trial of CRV431 for the treatment of NASH fibrosis in June. The study, called AMBITION, will enroll 18 adults with presumed NASH F2- or F3-stage...

May 19, 2020

Features

Amidst a global pandemic, two biotech companies offer innovative solutions

Since COVID-19 was first identified in China late last year, researchers have been working tirelessly to develop diagnostics, therapeutics and vaccines in an effort to prevent the spread of the SARS-CoV-2 virus. Many...

March 31, 2020

Markets

Analysts see strong rationale for Hepion CRV431’s use in severe COVID-19 cases

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CRV431, a cyclophilin inhibitor with antifibrotic and antiviral properties, may show some effect in the ongoing COVID-19 pandemic, according to Roth Capital Partners and Brookline...

March 20, 2020

Developments

Hepion’s CRV431 shows potential to treat idiopathic pulmonary fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive findings from a translational research study assessing the effects of CRV431 on lung tissue obtained from a patient with idiopathic pulmonary fibrosis (IPF). In the...

March 12, 2020

Developments

Hepion’s CRV431 shows potential to impact multiple types of fibrotic disease

Hepion Pharmaceuticals (NASDAQ:HEPA) reported results from in vitro studies showing that CRV431 can decrease production of the extracellular matrix (ECM) molecules, collagen and fibronectin, from fibroblastic cells. The...

February 19, 2020

Tag - HEPA

Hepion Pharma posts preclinical data supporting two-pronged approach treating COVID-19 with CRV431

Hepion advances to final dosing level in ongoing Phase 1 study of CRV431

Hepion Pharma CRV431 shows efficacy in kidney fibrosis

Hepion names drug development expert, Dr. Peter Wijngaard, to its board

Hepion advances to fourth dosing level in ongoing Phase 1 study of CRV431

Hepion CRV431 to advance to Phase 2a trial for NASH fibrosis

Amidst a global pandemic, two biotech companies offer innovative solutions

Analysts see strong rationale for Hepion CRV431’s use in severe COVID-19 cases

Hepion’s CRV431 shows potential to treat idiopathic pulmonary fibrosis

Hepion’s CRV431 shows potential to impact multiple types of fibrotic disease

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter